AK154

Phase 1Biologic

AAkeso

AK154 is one of 6 biologic programs targeting mRNA Vaccine. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MRNA VaccineNot yet recruiting

MRNA VaccinePhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in MRNA Vaccine

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 1

1 2

Personalized Neoantigen Tumor Vaccine

RRuijin Hospital

Phase 1

1 3

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 1

1 4

Mfolforinox

AAkeso

Phase 1

1 5

AK154

AAkeso

Phase 1

1 6

Moderna

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

MRNA Vaccine

NCT06913218

Clinical

Trials by Indication[1]

mRNA Vaccine1 trial

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Not yet recruiting·AAkeso·Phase 1·NCT06913218·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AK154. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AK154 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AK154. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAkeso

AK154

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

mRNA Vaccine1 trial

References

Drug Info

Quick Facts

Related News